Skip to main content
. 2021 Mar 4;11(9):4516–4530. doi: 10.7150/thno.54549

Figure 7.

Figure 7

PRADX promotes tumor cell growth and tumorigenesis. A-B CCK-8 assays showing the effect of PRADX knockdown on the viability of U87-MG, HT-29, N33 and SW480 cells. C-D Clonogenic assays showing the effect of PRADX knockdown on U87-MG, HT-29, N33, and SW480 cells. Representative images and the average number of colonies are shown. E Nude mice were subcutaneously injected with PRADX knockdown or control HT29 cells. Quantification of tumor volume and wet weight is shown. F-G Nude mice were orthotopically injected with PRADX knockdown or control U87-MG cells. Quantification of bioluminescent imaging signal intensities and Kaplan-Meier survival curve of nude mice are shown. H Immunohistochemistry of tumor tissues from xenograft models showing UBXN1, p-NF-κB and Ki-67 expression in PRADX knockdown and scramble groups. Scale bar, 40 μm. I Scheme showing PRADX-mediated recruitment of PRC2/DDX5 complex and regulation of NF-κB activity. The values in A, B, D, E and F are represented as mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.